

# Anthony Wing-Hung Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3243478/publications.pdf>

Version: 2024-02-01

407  
papers

27,821  
citations

3334

91  
h-index

7745

150  
g-index

415  
all docs

415  
docs citations

415  
times ranked

25832  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, 20, 78-84.	1.8	6
2	Association of genetic variations with NAFLD in lean individuals. <i>Liver International</i> , 2022, 42, 149-160.	3.9	33
3	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	8.9	12
4	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Caseâ€Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	4.3	28
5	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	4.9	12
6	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCII expression. <i>Nature Communications</i> , 2022, 13, 156.	12.8	28
7	Angiotensinâ€converting enzyme inhibitors prevent liverâ€related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	7.3	41
8	Recognising the clinically significant macrotrabecular massive variant of hepatocellular carcinoma. <i>Singapore Medical Journal</i> , 2022, , .	0.6	0
9	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , 2022, 2022, 1-13.	0.6	0
10	Letter: systematic review with metaâ€analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	3.7	1
11	Unique molecular characteristics of NAFLD-associated liver cancer accentuate $\beta$ -catenin/TNFRSF19-mediated immune evasion. <i>Journal of Hepatology</i> , 2022, 77, 410-423.	3.7	13
12	Risk of liverâ€related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	7.3	24
13	Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1131-1138.	2.8	5
14	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	5.0	5
15	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33
16	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	4.4	18
17	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	4.4	119
18	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	12.1	121

#	ARTICLE	IF	CITATIONS
19	Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. <i>Gut</i> , 2021, 70, 761-774.	12.1	382
20	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021, 73, 870-870.	7.3	1
21	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong's A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	5.8	26
22	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	2.2	12
23	Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1005-1015.	10.5	23
24	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.4	37
25	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	6.1	16
26	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	2.5	20
27	Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 543-550.	2.8	40
28	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	4.3	9
29	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	3.3	12
30	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.9	10
31	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	59
32	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1375-1382.	2.6	20
33	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , 2021, 41, 182-190.	3.6	5
34	Debate settled for elevated alanine aminotransferase in hepatitis B?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 750-751.	9.1	0
35	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	7.3	41
36	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	8.9	14

#	ARTICLE	IF	CITATIONS
37	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.6	1
38	Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1795-1808.	7.3	24
39	IDDF2021-ABS-0122...No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0
40	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.4	25
41	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	3.7	23
42	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. <i>Gut</i> , 2020, 69, 365-379.	12.1	117
43	Laparoscopic Hepatectomy (with or without Robotic Assistance) versus Radiofrequency Ablation as a Minimally Invasive Treatment for Very Early-Stage or Early-Stage Hepatocellular Carcinoma. <i>Digestive Surgery</i> , 2020, 37, 65-71.	1.2	17
44	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	1.3	156
45	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	12.1	27
46	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	5.5	135
47	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	3.7	54
48	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
49	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	4.4	21
50	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	3.7	49
51	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	3.9	75
52	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	7.7	28
53	EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13523-13535.	3.6	11
54	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	8.1	82

#	ARTICLE	IF	CITATIONS
55	Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10705-10713.	3.6	5
56	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.9	18
57	En bloc transdiaphragmatic lung resection for locally advanced hepatocellular carcinoma: a case report. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjaa084.	0.4	1
58	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , 2020, 73, 729-730.	3.7	0
59	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	3.4	38
60	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40
61	Endoscopic ultrasound-guided tissue acquisition with or without macroscopic on-site evaluation: randomized controlled trial. <i>Endoscopy</i> , 2020, 52, 856-863.	1.8	35
62	Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. <i>Journal of Pathology</i> , 2020, 251, 74-86.	4.5	9
63	Macromolecular proton fraction mapping based on spin-echo magnetic resonance imaging. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 3157-3171.	3.0	6
64	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	2.8	4
65	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	7.3	59
66	Unresolved issues of immune tolerance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 383-389.	5.1	16
67	Virtual multiplex immunohistochemistry: Application on cell block of effusion and aspiration cytology. <i>Diagnostic Cytopathology</i> , 2020, 48, 417-423.	1.0	10
68	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 128.	2.0	6
69	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	2.0	17
70	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study. <i>Journal of Clinical Oncology</i> , 2020, 38, 508-508.	1.6	0
71	IDDF2020-ABS-0200...Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients. , 2020, , .		0
72	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	2.8	28

#	ARTICLE	IF	CITATIONS
73	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	54
74	<i>Peptostreptococcus anaerobius</i> promotes colorectal carcinogenesis and modulates tumour immunity. <i>Nature Microbiology</i> , 2019, 4, 2319-2330.	13.3	281
75	Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. <i>Gastroenterology</i> , 2019, 157, 1630-1645.e6.	1.3	123
76	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	12.1	113
77	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019, 70, 971-981.	7.3	33
78	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	2.8	13
79	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019, 32, 1646-1656.	5.5	16
80	Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. <i>Journal of Pathology</i> , 2019, 249, 166-172.	4.5	26
81	Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. <i>Nutrition and Cancer</i> , 2019, 71, 954-970.	2.0	7
82	The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. <i>Cancer Letters</i> , 2019, 457, 98-109.	7.2	40
83	PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS $\geq 4$ ) and significant fibrosis (F $\geq 2$ ). <i>Journal of Hepatology</i> , 2019, 70, e134-e135.	3.7	1
84	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	3.7	14
85	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 260-262.	8.1	2
86	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9
87	Multiple modulatory activities of <i>Andrographis paniculata</i> on immune responses and xenograft growth in esophageal cancer preclinical models. <i>Phytomedicine</i> , 2019, 60, 152886.	5.3	15
88	Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter". <i>Journal of Hepatology</i> , 2019, 70, 1304.	3.7	0
89	Updates of pancreatic neuroendocrine neoplasm in the 2017 World Health Organization classification. <i>Surgical Practice</i> , 2019, 23, 42-47.	0.2	4
90	IDDF2019-ABS-0199...The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	IDDF2019-ABS-0325...Superior efficacy and long-term survival benefit of HDAC8 and PD-L1 co-blockade in liver cancer immunotherapy. , 2019, , .		0
92	IDDF2019-ABS-0174...Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. , 2019, , .		0
93	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2019, 114, 916-928.	0.4	57
94	Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection". Journal of Hepatology, 2019, 70, 573-574.	3.7	3
95	Cross-sectional area of the median nerve at the wrist: Comparison of sonographic, MRI, and cadaveric measurements. Journal of Clinical Ultrasound, 2019, 47, 122-127.	0.8	18
96	Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms. Hepatology, 2019, 70, 1011-1025.	7.3	60
97	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. Journal of Hepatology, 2019, 70, 361-370.	3.7	173
98	Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. Hpb, 2018, 20, 546-554.	0.3	36
99	miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death and Disease, 2018, 9, 92.	6.3	125
100	Non-invasive Assessment of Liver Disease. , 2018, , 163-179.		0
101	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. Hepatology, 2018, 67, 2302-2319.	7.3	16
102	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. Radiology, 2018, 287, 340-348.	7.3	4
103	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology, 2018, 16, 765-773.e2.	4.4	48
104	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. Modern Pathology, 2018, 31, 1381-1390.	5.5	41
105	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. Clinical Infectious Diseases, 2018, 67, 1278-1284.	5.8	39
106	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 484-491.	2.8	27
107	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017"Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 70-85.	2.8	358
108	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017"Part 2: Management and special groups. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 86-98.	2.8	117



#	ARTICLE	IF	CITATIONS
109	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance". <i>Journal of Hepatology</i> , 2018, 68, 208-209.	3.7	0
110	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territory-wide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	2.8	10
111	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	3.7	77
112	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	3.7	72
113	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. <i>Gut</i> , 2018, 67, 931-944.	12.1	138
114	EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. <i>Journal of Pathology</i> , 2018, 244, 394-407.	4.5	44
115	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018, 118, 248-257.	6.4	71
116	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	2.2	22
117	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2018, 16, 163-170.	1.8	21
118	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 89-89.	3.0	30
119	IDDF2018-ABS-0058...Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b " a territory-wide study of 21,182 subjects. , 2018, , .		0
120	IDDF2018-ABS-0106...Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
121	Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 150.	4.4	13
122	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, 5214.	12.8	66
123	Novel biomarkers GEP/ABC5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 524-530.	1.3	4
124	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1629-1638.	0.4	24
125	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 793-802.	3.7	79
126	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	3.7	360



#	ARTICLE	IF	CITATIONS
127	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS ONE, 2018, 13, e0199198.	2.5	6
128	EXOSC4 functions as a potential oncogene in development and progression of colorectal cancer. Molecular Carcinogenesis, 2018, 57, 1780-1791.	2.7	12
129	IDDF2018-ABS-0107â€¦Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). , 2018, , .		1
130	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
131	RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. Molecular Cancer, 2018, 17, 102.	19.2	58
132	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. Pathogens, 2018, 7, 63.	2.8	16
133	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 69, 1349-1356.	3.7	198
134	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. Clinical Chemistry, 2018, 64, 1239-1249.	3.2	60
135	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. Oncologist, 2018, 23, 1436-1445.	3.7	9
136	Abstract 4563: PD-L1 expression associated with treatment responses in colorectal cancer patients with XELOX/FOLFOX chemotherapy: Potential of checkpoint blockage and natural killer cell-based immunotherapy. , 2018, , .		1
137	Incorporating albuminâ€™bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 221-228.	2.8	47
138	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65, 54-64.	7.3	260
139	Exome and genome sequencing of nasopharynx cancer identifies NF-Î²B pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
140	Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology, 2017, 152, 1419-1433.e5.	1.3	308
141	Significant positive association of endotoxemia with histological severity in 237 patients with nonâ€™alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 175-182.	3.7	58
142	Fecal Immunochemical Test Predicts Histological Healing in Ulcerative Colitis: A Prospective Study Using the Geboes Score and Nancy Index. Gastroenterology, 2017, 152, S209.	1.3	1
143	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. Journal of Hepatology, 2017, 67, 577-584.	3.7	110
144	Topical Application of Mesenchymal Stromal Cells Ameliorated Liver Parenchyma Damage After Ischemia-Reperfusion Injury in an Animal Model. Transplantation Direct, 2017, 3, e160.	1.6	5

#	ARTICLE	IF	CITATIONS
145	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2017, 49, e2.	0.9	1
146	Reply to: "Serum HBsAg kinetics in clinical prediction". <i>Journal of Hepatology</i> , 2017, 67, 193-194.	3.7	0
147	The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP/PKA/EGFR/STAT3 axis. <i>Oncogene</i> , 2017, 36, 4135-4149.	5.9	32
148	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	2.8	44
149	Validating the ALBI grade: Its current and future use in HCC prognostication. <i>Journal of Hepatology</i> , 2017, 66, 661-663.	3.7	11
150	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.4	67
151	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	343
152	The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2017, 243, 418-430.	4.5	29
153	HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. <i>Journal of Clinical Pathology</i> , 2017, 70, 814-816.	2.0	2
154	A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). <i>Gastrointestinal Endoscopy</i> , 2017, 86, 1139-1146.e6.	1.0	32
155	GATAD1 Promotes Hepatocellular Carcinogenesis through Directly Inducing PTP4A3 and Activating Akt Pathway. <i>Gastroenterology</i> , 2017, 152, S1182.	1.3	0
156	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
157	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. <i>Clinical Chemistry</i> , 2017, 63, 1614-1623.	3.2	63
158	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3977-3985.	4.1	22
159	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	3.7	112
160	<i>Peptostreptococcus Anaerobius</i> Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. <i>Gastroenterology</i> , 2017, 152, S1010.	1.3	2
161	Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1071-1077.	1.3	26
162	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. <i>Current Hepatology Reports</i> , 2017, 16, 97-104.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 280-289.	3.9	38
164	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	2.8	152
165	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	3.7	267
166	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	2.8	16
167	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
168	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 506-514.	2.8	39
169	Primary hepatic gastrointestinal stromal tumor presented with rupture. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 65-66.	1.5	5
170	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2017, , 623-635.	0.1	3
171	A study on thromboembolism of patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 262-262.	1.6	1
172	CD133 and EpCAM as Biomarkers in Liver Diseases. <i>Biomarkers in Disease</i> , 2017, , 349-372.	0.1	1
173	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15679-e15679.	1.6	0
174	Endoscopic ultrasound of pancreatic lesions. <i>Journal of Visualized Surgery</i> , 2016, 2, 119-119.	0.2	6
175	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , 2016, 22, 7289.	3.3	138
176	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. <i>Journal of Digestive Diseases</i> , 2016, 17, 538-546.	1.5	31
177	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	2.8	151
178	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	7.3	101
179	Reply. <i>Hepatology</i> , 2016, 64, 1820-1821.	7.3	0
180	Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor- $\kappa$ B in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2016, 238, 651-664.	4.5	46

#	ARTICLE	IF	CITATIONS
181	Reply. <i>Hepatology</i> , 2016, 64, 685-686.	7.3	1
182	MET DNA Alterations in NSCLC—Reply. <i>Clinical Cancer Research</i> , 2016, 22, 3699-3699.	7.0	0
183	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
184	A Rare Cause of Ischemic Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e109-e110.	4.4	0
185	Virus and Host Testing to Manage Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2016, 62, S298-S305.	5.8	12
186	Comments on “Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients”. <i>European Journal of Cancer</i> , 2016, 68, 203-205.	2.8	0
187	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. <i>Hepatology</i> , 2016, 64, 1507-1517.	7.3	23
188	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	8.1	152
189	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	2.9	21
190	Applicability of albumin–bilirubin–based Japan integrated staging score in hepatitis B–associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1766-1772.	2.8	47
191	Mechanism and Natural Course of Tumor Involution in Hepatocellular Carcinoma Following Transarterial Ethanol Ablation. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 1136-1143.	2.0	3
192	Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1300-1306.	2.8	103
193	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	12.1	39
194	Risk of Advanced Adenomas in Siblings of Individuals With Advanced Adenomas: A Cross-Sectional Study. <i>Gastroenterology</i> , 2016, 150, 608-616.	1.3	25
195	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
196	Personalized therapy for hepatocellular carcinoma: Where are we now?. <i>Cancer Treatment Reviews</i> , 2016, 45, 77-86.	7.7	51
197	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1481-1489.e5.	4.4	51
198	MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 3048-3056.	7.0	352

#	ARTICLE	IF	CITATIONS
199	Dysregulated Lysine Acetyltransferase 2B Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 726-734.	1.3	26
200	Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , 2016, 12, 5-6.	9.6	4
201	Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development. <i>Oncogene</i> , 2016, 35, 2133-2144.	5.9	20
202	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	12.1	386
203	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3566-3566.	1.6	1
204	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. <i>Biomarkers in Disease</i> , 2016, , 1-13.	0.1	0
205	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015, 121, 2720-2729.	4.1	43
206	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1529-1535.	2.8	14
207	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
208	Phase I/II study of tamsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	2.6	96
209	Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1292-1300.	1.1	51
210	Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. <i>EBioMedicine</i> , 2015, 2, 497-498.	6.1	0
211	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	4.4	52
212	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	3.7	398
213	Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1040-1048.	2.8	7
214	PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	2.8	125
215	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.3	18
216	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1306-1314.	0.4	240

#	ARTICLE	IF	CITATIONS
217	Irreversible Electroporation of the Femoral Neurovascular Bundle: Imaging and Histologic Evaluation in a Swine Model. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1212-1220.e1.	0.5	5
218	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	3.7	49
219	EUS-guided alcohol injection of pancreatic neuroendocrine tumor. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 167.	1.0	8
220	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	3.7	83
221	Wnt/ $\beta$ -Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. <i>Cancer Letters</i> , 2015, 362, 97-105.	7.2	114
222	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4138-4148.	1.5	206
223	New simple prognostic score for primary biliary cirrhosis: Albumin $\times$ bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	2.8	95
224	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 973-983.	3.4	9
225	Lymphoepithelioma-like Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 304-312.	3.7	66
226	A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. <i>Pathology</i> , 2015, 47, 178-181.	0.6	11
227	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2015, 9, 481-483.	4.2	2
228	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	3.7	147
229	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	4.4	11
230	A Pancreatic Mass With Multiple Hepatic Lesions. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, e3-e4.	4.4	11
231	Noninvasive assessments of liver fibrosis with transient elastography and $\alpha$ -fetoprotein index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	2.8	12
232	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	2.5	28
233	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	2.5	77
234	Non-Hodgkin's Lymphoma of the Knee: A Case Report. <i>Iranian Journal of Radiology</i> , 2015, 12, e7583.	0.2	5



#	ARTICLE	IF	CITATIONS
235	CD133 and EpCAM as Biomarkers in Liver Diseases. <i>Exposure and Health</i> , 2015, , 1-24.	4.9	0
236	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4073-4073.	1.6	0
237	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2014, 59, 1714-1723.	5.8	79
238	In vivo appearances of gallbladder carcinoma under magnifying endoscopy and probe-based confocal laser endomicroscopy after endosonographic gallbladder drainage. <i>Endoscopy</i> , 2014, 46, E13-E14.	1.8	19
239	Case of hepatocellular carcinoma with multicentric Castleman's disease. <i>Surgical Practice</i> , 2014, 18, 154-155.	0.2	0
240	Metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 716-726.	3.7	20
241	Noninvasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 197-208.	3.7	61
242	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 883-893.	3.7	113
243	Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 768-776.	3.4	61
244	EBV-associated lymphoepithelioma-like cholangiocarcinoma: a rare variant of intrahepatic cholangiocarcinoma with favourable outcome. <i>Histopathology</i> , 2014, 65, 674-683.	2.9	51
245	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.8	28
246	A Rare Tumor of the Common Hepatic Duct Causing Biliary Obstruction. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, e29-e30.	4.4	0
247	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	3.7	69
248	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 339-345.	3.7	227
249	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. <i>Cancer Cell</i> , 2014, 25, 335-349.	16.8	254
250	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 532-539.	3.7	95
251	A Rare Cause of Protein-Losing Enteropathy. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, e49-e50.	4.4	0
252	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	2.9	20



#	ARTICLE	IF	CITATIONS
253	Expression of stemness markers (<sc>CD</sc>133 and Ep<sc>CAM</sc>) in prognostication of hepatocellular carcinoma. <i>Histopathology</i> , 2014, 64, 935-950.	2.9	75
254	Fatty Pancreas, Insulin Resistance, and Î²-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.4	194
255	Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 80.	4.4	58
256	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	4.4	51
257	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014, 60, 809-815.	3.7	34
258	Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. <i>Abdominal Imaging</i> , 2014, 39, 1241-1246.	2.0	23
259	MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. <i>Oncology Reports</i> , 2014, 31, 2071-2078.	2.6	21
260	Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. <i>Oncology Reports</i> , 2014, 31, 2579-2586.	2.6	14
261	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6029-6029.	1.6	1
262	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. <i>Chinese Journal of Cancer</i> , 2014, 33, 481-91.	4.9	22
263	Abstract 1245: Reactivation of growth/differentiation factor 1 contributes to the chemopreventive effect of 5-aza-2â€²deoxycytidine in gastric cancer. , 2014, , .		0
264	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	9.6	88
265	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	4.4	64
266	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis <sc>B</sc>: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	2.8	35
267	Treatment of nonâ€alcoholic steatohepatitis with <i><sc>P</sc>hyllanthus urinaria</i>: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	2.8	23
268	Peginterferon therapy for chronic hepatitis B: one size fits all?. <i>Gut</i> , 2013, 62, 185-187.	12.1	7
269	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	7.3	408
270	Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 58, 1165-1173.	3.7	160

#	ARTICLE	IF	CITATIONS
271	Case report and a review of the literature of two patients with gastric <scp>MALT</scp>oma and pulmonary metastasis. <i>Surgical Practice</i> , 2013, 17, 28-30.	0.2	0
272	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. <i>Journal of Hepatology</i> , 2013, 59, 536-542.	3.7	254
273	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	7.3	267
274	Liver fibrosis progression in chronic hepatitis <scp>B</scp> patients positive for hepatitis <scp>B</scp> e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	2.8	22
275	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 122-129.	3.6	14
276	Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. <i>Journal of Thoracic Oncology</i> , 2013, 8, 883-891.	1.1	67
277	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	1.0	12
278	SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3 $\beta$ /E-catenin signaling. <i>Hepatology</i> , 2013, 57, 2287-2298.	7.3	179
279	An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment. <i>Journal of Thoracic Oncology</i> , 2013, 8, e107-e108.	1.1	7
280	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	4.2	96
281	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis "A Longitudinal Study. <i>PLoS ONE</i> , 2013, 8, e62885.	2.5	266
282	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan $\text{\textcircled{R}}$ ): applying the cut-offs of M probe to XL probe. <i>Annals of Hepatology</i> , 2013, 12, 402-412.	1.5	28
283	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013, 12, 256-262.	1.5	252
284	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e54522.	2.5	46
285	MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. <i>Carcinogenesis</i> , 2012, 33, 1134-1141.	2.8	84
286	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	12.1	423
287	GEF $\beta$ 1 overexpression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling. <i>Journal of Pathology</i> , 2012, 228, 575-585.	4.5	34
288	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.4	292

#	ARTICLE	IF	CITATIONS
289	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	1.6	167
290	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	3.7	196
291	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®. <i>Journal of Hepatology</i> , 2012, 56, 833-839.	3.7	218
292	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. <i>Journal of Hepatology</i> , 2012, 56, 1363-1370.	3.7	198
293	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	3.7	61
294	Improving transient elastography performance for detecting hepatitis B cirrhosis. <i>Digestive and Liver Disease</i> , 2012, 44, 61-66.	0.9	26
295	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. <i>Annals of Hepatology</i> , 2012, 11, 284-293.	1.5	22
296	Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. <i>Journal of Pathology</i> , 2012, 226, 471-481.	4.5	62
297	45 YEAR OLD MAN WITH A PINEAL REGION TUMOR FOR OVER 15 YEARS. <i>Brain Pathology</i> , 2012, 22, 255-258.	4.1	5
298	Response-guided therapy by hepatitis B surface antigen level for peginterferon therapy: What is next?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 420-421.	2.8	3
299	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012, 57, 221-231.	2.3	7
300	Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer. <i>PLoS ONE</i> , 2012, 7, e33919.	2.5	82
301	Abstract 4127: MiR-183/96/182 cluster confers cell motile advantages in hepatocellular carcinoma. , 2012, , .		0
302	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011, 60, 829-836.	12.1	219
303	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011, 55, 497.	3.7	4
304	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	3.7	280
305	Renal myxoid tumour of uncertain malignant potential. <i>Pathology</i> , 2011, 43, 287-289.	0.6	2
306	Primary perivascular epithelioid cell tumour (PEComa) of the urinary bladder. <i>Pathology</i> , 2011, 43, 746-749.	0.6	11

#	ARTICLE	IF	CITATIONS
307	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	1.0	82
308	Benign epithelioid schwannoma of intraparotid facial nerve. <i>Pathology</i> , 2011, 43, 280-282.	0.6	5
309	Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 8-12.	2.8	27
310	Chronic hepatitis B in Asia—new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 131-137.	2.8	68
311	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 419-420.	2.8	4
312	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011, 31, 1047-1053.	3.9	31
313	A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. <i>Oncogene</i> , 2011, 30, 4464-4475.	5.9	75
314	A subset of breast cancer predisposes to brain metastasis. <i>Medical Molecular Morphology</i> , 2011, 44, 15-20.	1.0	42
315	Malignant pigmented clear cell epithelioid cell tumor (PEComa) in an adolescent boy with widespread metastases: a rare entity in this age group. <i>Pediatric Radiology</i> , 2011, 41, 1587-1590.	2.0	9
316	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011, 60, 1721-1727.	12.1	248
317	Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth. <i>Cancer Research</i> , 2011, 71, 4138-4149.	0.9	189
318	Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. <i>Clinical Cancer Research</i> , 2011, 17, 2130-2139.	7.0	224
319	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen—Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	4.0	110
320	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2011, 6, e22888.	2.5	73
321	Second-Trimester Detection of Mowat-Wilson Syndrome Using Comparative Genomic Hybridization Microarray Testing. <i>Obstetrics and Gynecology</i> , 2010, 115, 462-465.	2.4	16
322	Correlation of biomarkers in head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 795-800.	1.9	16
323	Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2010, 10, 253.	2.6	68
324	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	7.3	1,052

#	ARTICLE	IF	CITATIONS
325	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	7.3	100
326	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 1232-1241.	7.3	226
327	A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2409-2414.	2.3	8
328	Reduced <i>CRYL1</i> expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis. <i>Journal of Pathology</i> , 2010, 220, 348-360.	4.5	22
329	Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1095-1103.	3.7	110
330	Association of the POU class 2 homeobox 1 gene ( <i>POU2F1</i> ) with susceptibility to Type 2 diabetes in Chinese populations. <i>Diabetic Medicine</i> , 2010, 27, 1443-1449.	2.3	22
331	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1726-1731.	2.8	82
332	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010, 59, 969-974.	12.1	538
333	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	12.1	0
334	MiR-222 Overexpression Confers Cell Migratory Advantages in Hepatocellular Carcinoma through Enhancing AKT Signaling. <i>Clinical Cancer Research</i> , 2010, 16, 867-875.	7.0	221
335	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
336	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.4	62
337	Predictors of invasion in needle core biopsies of the breast with ductal carcinoma in situ. <i>Modern Pathology</i> , 2010, 23, 737-742.	5.5	27
338	EUS-guided transduodenal biliary drainage. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 186-187.	1.0	5
339	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	3.9	22
340	Reply:. <i>Hepatology</i> , 2009, 50, 2049-2050.	7.3	3
341	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009, 124, 2766-2770.	5.1	197
342	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 387-396.	3.7	108

#	ARTICLE	IF	CITATIONS
343	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	2.0	363
344	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	2.8	104
345	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1113-1120.	4.4	46
346	HER2 Expression Predicts Improved Survival in Patients with Cervical Node-Positive Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 141, 467-473.	1.9	15
347	Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong. <i>Journal of Hepatology</i> , 2009, 51, 1088-1090.	3.7	11
348	Predictors of Treatment Response in Chronic Hepatitis B. <i>Drugs</i> , 2009, 69, 2167-2177.	10.9	40
349	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	4.4	70
350	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	4.4	75
351	Modulation of LMP2A Expression by a Newly Identified Epstein-Barr Virus-Encoded MicroRNA miR-BART22. <i>Neoplasia</i> , 2009, 11, 1174-1177.	5.3	176
352	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009, 58, 111-117.	12.1	198
353	Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridization. <i>International Journal of Oncology</i> , 2009, 34, 963-70.	3.3	14
354	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-99.	1.0	14
355	A review of the natural history of chronic hepatitis B in the era of transient elastography. <i>Antiviral Therapy</i> , 2009, 14, 489-499.	1.0	34
356	Genetic polymorphisms of adiponectin and tumor necrosis factor- $\alpha$ and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	2.8	60
357	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	4.4	24
358	984 COMBINATION OF THE MEDIAN AND VARIABILITY OF LIVER STIFFNESS MEASUREMENTS BY TRANSIENT ELASTOGRAPHY IMPROVES THE ACCURACY OF DIAGNOSING ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2008, 48, S367.	3.7	2
359	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	4.4	143
360	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???	0.4	101



#	ARTICLE	IF	CITATIONS
361	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.4	83
362	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
363	Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. <i>Carcinogenesis</i> , 2008, 29, 1648-1654.	2.8	33
364	Fine needle aspiration cytology of breast cancer in women aged 70 years and older. <i>Pathology</i> , 2008, 40, 573-579.	0.6	0
365	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 571-579.	1.0	33
366	Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2008, 13, 1029-1037.	1.0	3
367	Familial extrarenal Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2007, 42, 1826-1830.	1.6	8
368	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	4.4	320
369	Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 3558-3565.	1.5	47
370	Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. <i>Antiviral Therapy</i> , 2007, 12, 345-53.	1.0	28
371	Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-23.	1.0	8
372	Two-year Lamivudine treatment for Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial. <i>Antiviral Therapy</i> , 2007, 12, 345-354.	1.0	76
373	Virological Response to Different Combination Regimes of Peginterferon $\alpha$ -2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007, 12, 815-823.	1.0	28
374	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	4.4	181
375	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1215-1222.	3.7	88
376	Hepatocellular Carcinoma and Hepatitis B Virus. <i>Seminars in Liver Disease</i> , 2006, 26, 153-161.	3.6	198
377	Phylogenetic, Virological, and Clinical Characteristics of Genotype C Hepatitis B Virus with TCC at Codon 15 of the Precore Region. <i>Journal of Clinical Microbiology</i> , 2006, 44, 681-687.	3.9	23
378	Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-71.	1.0	8



#	ARTICLE	IF	CITATIONS
379	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic HBeAg-Negative Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 465-471.	1.0	28
380	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1357-1364.	7.3	77
381	Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B. <i>Current Hepatitis Reports</i> , 2005, 4, 27-33.	0.3	0
382	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon- $\alpha$ 2b and Lamivudine with Lamivudine Alone. <i>Annals of Internal Medicine</i> , 2005, 142, 240.	3.9	248
383	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. <i>American Journal of Gastroenterology</i> , 2005, 100, 616-623.	0.4	200
384	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005, 13, 175-182.	2.7	28
385	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, 2205-2211.	0.4	29
386	Congenital systemic Langerhans cell histiocytosis presenting as hydrops fetalis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1843-1847.	1.5	12
387	Congenital systemic Langerhans cell histiocytosis presenting as hydrops fetalis. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2005, 94, 1843-1847.	1.5	5
388	Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. <i>Oncology Reports</i> , 2005, 13, 937-41.	2.6	25
389	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monophylaxis. <i>Clinical Transplantation</i> , 2004, 18, 295-300.	1.6	33
390	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. <i>Liver International</i> , 2004, 24, 611-618.	3.9	48
391	Effect of age and disease on taste perception. <i>Journal of Pain and Symptom Management</i> , 2004, 28, 28-34.	1.2	43
392	Frequent hypermethylation of promoter region of <i>RASSF1A</i> in tumor tissues and voided urine of urinary bladder cancer patients. <i>International Journal of Cancer</i> , 2003, 104, 611-616.	5.1	97
393	Hypermethylation of the tumor suppressor gene RASSF1A and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. <i>International Journal of Cancer</i> , 2003, 105, 204-209.	5.1	65
394	Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1277-1279.	3.9	127
395	Use of Hepatitis B Virus DNA Quantitation To Predict Hepatitis B e Antigen Reversion in Cases of Chronic Hepatitis B. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4793-4795.	3.9	22
396	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. <i>World Journal of Gastroenterology</i> , 2003, 9, 2695.	3.3	50

#	ARTICLE	IF	CITATIONS
397	Renal Outcome in Type 2 Diabetic Patients With or Without Coexisting Nondiabetic Nephropathies. <i>Diabetes Care</i> , 2002, 25, 900-905.	8.6	118
398	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. <i>American Journal of Gastroenterology</i> , 2002, 97, 2629-2633.	0.4	27
399	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 406-412.	0.4	131
400	Changing scene in hepatitis B serology interpretation. <i>British Journal of Hospital Medicine</i> , 2002, 63, 16-19.	0.2	18
401	Factors associated with viral breakthrough in lamivudine monotherapy of hepatitis B virus recurrence after liver transplantation. <i>Journal of Medical Virology</i> , 2002, 68, 182-187.	5.0	81
402	Risk Factors for Active Liver Disease in Hbeag-Negative Chronic Hepatitis B Virus-Infected Patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 3547-3551.	0.4	31
403	Characterization of early IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 2000, 36, 703-708.	1.9	34
404	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 3547-3551.	0.4	19
405	Extramullary Nasal Plasmacytoma - An Unusual Clinical Entity. <i>Ear, Nose and Throat Journal</i> , 1996, 75, 171-173.	0.8	10
406	Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. <i>Oncology Reports</i> , 0, , .	2.6	17
407	Clinical Application, Performance, and Common Pitfalls of Ultrasound-guided Pleural Biopsy: Our Local Experience. <i>Hong Kong Journal of Radiology</i> , 0, , 103-110.	0.1	0